Oriental Wave

Oriental Wave (Beijing) Biology Co., Ltd. is a Chinese biotechnology company specializing in the development and commercialization of recombinant protein therapeutics for regenerative medicine and wound care. The company is most notable for its pioneering work with recombinant human acidic fibroblast growth factor (rh-aFGF), which was one of the first drugs of its kind to receive regulatory approval globally. Oriental Wave focuses on addressing unmet medical needs in chronic wound management, particularly for diabetic foot ulcers and severe burns. The company operates integrated research and large-scale GMP manufacturing facilities in Beijing to support its clinical and commercial operations. Through strategic collaborations with academic and military medical institutions, Oriental Wave continues to advance the application of growth factor therapies in the Chinese market.